https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Comparison of BICAMS and ARCS for assessment of cognition in multiple sclerosis and predictive value of employment status https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38853 r = 0.3–0.5; P ≤ 0.05). Total ARCS predicts cognitive impairment with good sensitivity and specificity relative to the BICAMS tests (AUC = 0.8; P = 0.00045). Total ARCS detects higher levels of impairment than BICAMS in MS patients (44% versus 21%). The memory domain of the ARCS and the BVMT-R were the best predictors of employment status (OR = 1.12 and 1.14, P  < 0.05). Conclusion: BICAMS and ARCS have comparable sensitivity for cognitive impairment in MS. Memory assessment from either tests is the best predictor of employment status; however, the BICAMS is a better predictor of work productivity.]]> Wed 23 Nov 2022 15:41:25 AEDT ]]> Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 50-year study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33281 Tue 25 Sep 2018 11:08:20 AEST ]]> Neurometabolic changes in multiple sclerosis: Fingolimod versus beta interferon or glatiramer acetate therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53309 .05). Compared to HCs, both RRMS cohorts showed volume changes in white matter (−13%), gray matter (−16%), and cerebral spinal fluid (CSF) (+17-23%), as well as reduced NAA (−17%, p =.001, hippocampus), (−7%, p =.001, PCG), and (−9%, p =.001, PFC). MRI/S metrics in three regions were moderately correlated with cognition and fatigue functions. Conclusion: While both treatment arms showed overall similar volumetric and neurometabolic profiles, longitudinal studies are warranted to clarify neurometabolic changes and associations with treatment efficacy.]]> Tue 21 Nov 2023 12:02:21 AEDT ]]> Do people with multiple sclerosis receive appropriate support from the National Disability Insurance Scheme matching their level of disability? A description of disease 'burden and societal cost in people with multiple sclerosis in Australia' (BAC-MS) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44317 Tue 11 Oct 2022 16:19:33 AEDT ]]> 2D in-vivo L-COSY spectroscopy identifies neurometabolite alterations in treated multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36572 Tue 09 Jun 2020 11:40:47 AEST ]]> Improving patient outcomes following total knee arthroplasty: identifying rehabilitation pathways based on modifiable psychological risk and resilience factors https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39917 Thu 30 Jun 2022 11:48:31 AEST ]]> Anxiety levels are independently associated with cognitive performance in an Australian multiple sclerosis patient cohort https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31520 Sat 24 Mar 2018 08:43:53 AEDT ]]> Spiral MRSI and tissue segmentation of normal-appearing white matter and white matter lesions in relapsing remitting multiple sclerosis patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42377 Mon 22 Aug 2022 14:29:24 AEST ]]> Biochemical Correlations with Fatigue in Multiple Sclerosis Detected by MR 2D Localized Correlated Spectroscopy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43429 P ≤ .05). Only GPC showed positive correlation with all fatigue domains (r = .537, P ≤ .05). On the other hand, Glx-upper, NAA-2, GSH+Hca, and fucose-3 showed negative correlations with all fatigue domains (r = –.345 to –.580, P ≤ .05). While tyrosine showed positive correlation with MFIS (r = .499, P ≤ .05), cognitive fatigue was negatively correlated with total GSH (r = –.530, P ≤ .05). No correlations were found between lesion load or brain volumes with fatigue score. CONCLUSIONS: Our results suggest that fatigue in MS is strongly correlated with an imbalance in neurometabolites but not structural brain measurements.]]> Mon 19 Sep 2022 09:29:20 AEST ]]> Fast magnetic resonance spectroscopic imaging techniques in human brain-applications in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30630 1H-MRS) and localization techniques principles, different fast MRSI techniques will be discussed from their initial development to the recent innovations with particular emphasis on their capacity to record neurochemical changes in the brain in a variety of pathologies. The clinical applications of whole brain fast spectroscopic techniques, can assist in the assessment of neurochemical changes in the human brain and help in understanding the roles they play in disease. To give a good example of the utilities of these techniques in clinical context, MRSI application in multiple sclerosis was chosen. The available up to date and relevant literature is discussed and an outline of future research is presented.]]> Mon 11 Mar 2019 12:08:59 AEDT ]]> Diurnal stability and long-term repeatability of neurometabolites using single voxel 1H magnetic resonance spectroscopy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36797 Mon 06 Jul 2020 16:25:41 AEST ]]> Evaluation of MS related central fatigue using MR neuroimaging methods: scoping review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47726 Fri 24 Feb 2023 14:56:06 AEDT ]]> Reliability of neurometabolite detection with two-dimensional localized correlation spectroscopy at 3T https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47224 Fri 16 Dec 2022 10:37:25 AEDT ]]> Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30423 Fri 03 Dec 2021 10:34:50 AEDT ]]>